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Abstract
Introduction: Adiponectin has been implicated in the pathogenesis of osteoarthritis (OA). We studied the effects
of adiponectin on the OA cartilage homeostasis.
Methods: Immunohistochemical analysis was performed to evaluate differential expression of adiponectin
receptors (AdipoRs) in nonlesional and lesional areas of OA cartilage. Cartilage and chondrocytes from the knee
joints of primary OA patients were cultured in the presence of adiponectin (0~30 μg/ml). The levels of total nitric
oxide (NO), matrix metalloproteinase (MMP)-1, -3, and -13, and tissue inhibitor of metalloproteinase (TIMP)-1 were
measured in the conditioned media. The levels of inducible NO synthase (iNOS) and MMPs were determined with
the quantitative real-time reverse transcription-polymerase chain reaction. The concentrations of collagenase-
cleaved type II collagen neoepitope (C1-2C) were determined in the supernatant of adiponectin-stimulated OA
cartilage explants. The effects of kinase and NOS inhibitors were evaluated in the adiponectin-stimulated
chondrocytes.
Results: The expression levels of both AdipoR1 and AdipoR2 were significantly higher in lesional than in
nonlesional areas of OA cartilage. The increased rate of AdipoR1-positive chondrocytes was twice that of AdipoR2-
positive chondrocytes when compared between nonlesional and lesional areas. Adiponectin-stimulated OA
chondrocytes showed increased total NO and MMP-1, -3, and -13 levels compared with nonstimulated cells. The
TIMP-1 level was not affected. The C1-2C levels were increased by adiponectin in OA cartilage explant culture.
AMP-activated protein kinase (AMPK) and c-Jun N-terminal kinase (JNK) inhibitors (compound C and SP600125)
significantly suppressed adiponectin-induced production of total NO and MMP-1, -3, and -13. Inducible NOS
inhibitors enhanced the expression of the adiponectin-induced MMPs.
Conclusions: Adiponectin causes matrix degradation in OA cartilage and increases MMPs and iNOS expression via
the AMPK and JNK pathways in human OA chondrocytes. The catabolic effects of adiponectin may be
counteracted by NO.
Introduction
Obesity has long been considered a risk factor for
osteoarthritis (OA) [1-4]. It has been reported that obe-
sity increases the incidence of OA, particularly in
weight-bearing joints such as knees [4], and weight
reduction is correlated with decreased progression of
OA. A prevailing hypothesis is that obesity increases
mechanical loading across the articular cartilage, which
leads to cartilage degeneration [5]. However, obesity also
is associated with OA in non-weight-bearing joints such
as finger joints, which suggests that metabolic factors
contribute to the high prevalence of OA in obese
subjects [6].
Adipose tissue is a highly active endocrine organ that
secretes many hormones involved in energy metabolism,
inflammation, and immune response. Such hormones,
collectively termed adipokines, exhibit cytokine-like
actions including anti- and pro-inflammatory effects [7].
Adiponectin has been considered one of adipokines
implicated in OA pathogenesis, based on the following
clinical observations: (a) plasma adiponectin levels were
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any medium, provided the original work is properly cited.significantly higher in OA patients than in healthy con-
trols [8], and (b) higher plasma adiponectin levels were
observed in female patients with erosive hand OA than
in those with nonerosive OA [9]. In adddition, adipo-
nectin has been detected in the OA synovial fluids, and
its receptors are expressed in the joint tissues [10-13].
However, only few studies examined its biologic roles in
OA pathogenesis, and the results have been controver-
sial. Chen et al. [12] showed that human cartilage
expressed only AdipoR1. However, both AdipoR1 and
AdipoR2 were expressed in human cartilage and chon-
drocytes in the study of Lago et al. [13]. In addition,
Chen et al.[ 1 2 ]r e p o r t e dt h a ta d i p o n e c t i nu p r e g u l a t e s
tissue inhibitor of metalloproteinase (TIMP)-2 and
downregulates IL-1b-induced matrix metalloproteinase
(MMP)-13 in OA chondrocytes, whereas Lago et al. [13]
showed that adiponectin induces nitric oxide synthase
(NOS), IL-6, MMP-3, MMP-9, and MCP-1 in murine
ATDC5 chondrogenic cell lines. Further to elucidate the
effect of adiponectin on OA cartilage homeostasis, we
investigated adiponectin-induced catabolic activity in
OA chondrocytes and matrix degradation of cartilage
explant.
Adiponectin activates intracellular signaling pathway
by activation of 5’-AMP-activated protein kinase
(AMPK) [14]. It was previously reported that adiponec-
tin stimulates the AMPK-PI3-K pathway in the murine
chondrocytic ATDC5 cell line and AMPK/p38/IKKab in
human synovial fibroblasts [13,15]. However, signaling
pathways downstream to AMPK have not been exten-
sively investigated in the human chondrocytes. There-
fore, we also studied the intracellular signaling pathways
involved in adiponectin-induced MMPs and NO
production.
Materials and methods
Study subjects
Cartilage was obtained from the knee joints of 12 pri-
mary OA patients at the time of knee-replacement sur-
gery (six for immunohistochemical study and six for in
vitro stimulation experiments). All study subjects had
symptomatic OA with Kellgren-Lawrence grade 3 or 4
in their index knees. They were all women with a mean
age of 71.4 years (range, 59 to 80 years), and their mean
body mass index (BMI) was 26.1 kg/m
2 (range, 21.4 to
30.1 kg/m
2). This study was approved by the Institu-
tional Review Board of Seoul National University Bun-
dang Hospital (IRB No. B-0607/035-018), and written
informed consent was obtained from study participants.
Assessment of AdipoR1 and AdiopoR2 expression by
immunohistochemistry
The postsurgical femoral cartilage samples obtained from
six patients (mean age, 70.0 years; mean BMI, 26.8 kg/m
2)
were fixed in 4% buffered paraformaldehyde for 2 days
and decalcified with buffered EDTA (20% EDTA, pH
7.4). After dehydration and embedding in paraffin, sec-
tions were cut at a thickness of 4 μm, deparaffinized in
xylene, and rehydrated in graded ethanol. Serial sections
from each case were stained with hematoxylin and eosin
and rabbit antibodies against human AdipoR1 (Phoenix
Pharmaceuticals, St Joseph, MO, USA; catalog no. H-
001-44) and AdiopR2 (catalog no. H-001-23). The suc-
ceeding steps were performed automatically at 37°C by
using the Benchmark XT Slide Staining System Specifica-
tions (Ventana Medical Systems, Tucson, AZ, USA).
Antigen retrieval was performed by immersing slides in
citrate buffer (pH 6.0) for 15 minutes, and endogenous
peroxidases were blocked with 1% H2O2 for 4 minutes.
The sections were incubated with anti-human adiponec-
tin receptors at the dilution of 1:100 for 60 minutes at
room temperature. To visualize the immunostaining, the
Ultravision LP kit (Lab Vision, Fremont, CA, USA) was
used. The slides were stained by using a diaminobenzi-
dine (DAB) detection kit and counterstained with hema-
toxylin. Specimens were evaluated under light
microscopy by an expert pathologist (J-H.C.) and scored
based on a semiquantitative approach of percentage of
positive chondrocytes (0 to 100%) and staining intensity
(0, negative; 1, weak; 2, moderate; 3, strong) in the
lesional and nonlesional areas of each cartilage sample.
The number of stained cells (staining intensity score, ≥1)
and total cells were counted in at least three randomly
selected high-power fields (150 cells or more) for each
area of cartilage samples.
Primary culture of OA chondrocytes
The cartilage portions with less than 50% of thickness
loss were harvested from postsurgical cartilage samples
of another six patients (mean age, 72.6 years; mean
BMI, 26.1 kg/m
2), and chondrocytes were released by
enzymatic digestion with 0.2% pronase (Sigma-Aldrich,
St. Louis, MO, USA) and 0.3% clostridial collagenase
(Worthington, Freehold, NJ, USA). Isolated chondro-
cytes were plated in poly-2 hydroxyethyl methacrylate
(HEMA; Sigma-Aldrich)-coated 60-mm-diameter dishes
(1 × 10
6 cells/dish) or 24-well plates (2.5 × 10
5 cells/
well) and cultured in Dulbecco’s Modified Eagle Med-
ium (DMEM) containing 10% fetal bovine serum (FBS),
100 IU/ml penicillin, and 100 μg/ml streptomycin at 37°
C in a humidified 5% CO2 atmosphere. The culture
medium was changed every 2 to 3 days in suspension
culture, and chondrocytes were stimulated 5 to 6 days
after isolation. Nonadherent culture in HEMA-coated
dishes has been described as a means of maintaining the
chondrocyte-specific phenotype for up to 3 months [16].
To prepare a 10 × stock solution, poly-HEMA was dis-
solved at 120 mg/ml in 95% ethanol, and the solution
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undissolved materials, the stock solution was diluted
with 95% ethanol to a final concentration of 12 mg/ml.
Culture dishes or plates were coated with 0.1 ml/cm
2 of
the diluted poly-HEMA solution and then air-dried
uncovered in a sterile environment for 2 days.
Cell treatments
OA chondrocytes were stimulated with the full-length
adiponectin at 0, 1, 10, or 30 μg/ml for 24 hours (Adipo-
Gen, Seoul, South Korea) in FBS-free DMEM. The full-
length adiponectin used in our study was a lyophilized
form of the FLAG-tagged recombinant human adiponec-
tin expressed by HEK 293 cells. When indicated, NOS
inhibitors were added in the presence of adiponectin; 2
mM L-N
G-monomethyl arginine citrate (L-NMMA; Cal-
biochem, San Diego, CA, USA), a nonselective NOS inhi-
bitor, and 50 μM of L-N
6-(1-iminoethyl)-lysine (L-NIL;
BioMol International, Plymouth Meeting, MA, USA), a
selective iNOS inhibitor.
To ascertain the adiponectin-related signaling path-
ways, OA chondrocytes were stimulated with adiponec-
tin in the presence of a kinase inhibitor; 10 μM
SB202190 for p38 MAP kinase (Alexis Biochemicals,
Farmingdale, MI, USA), 20 μM SP600125 for c-Jun
N-terminal kinase (JNK; BioMol International), 50 μM
U0126 for extracellular-regulated kinase (ERK; Promega,
Madison, WI, USA), 20 μM compound C for AMP-acti-
vated protein kinase (AMPK; Calbiochem), 50 μM
LY294002 for Akt (BioSource International, Camarillo,
CA, USA), and 100 μg/ml SN50 for nuclear factor
kappa B (NF-B; Alexis Biochemicals). No significant
cytotoxicity was found for OA chondrocytes by the
kinases or NOS inhibitors up to 24 hours of exposure
(data not shown).
Measurement of NO and MMPs/TIMP-1 levels in culture
media
The levels of total NO were measured by using a modi-
fied Griess reaction (Promega). The concentrations of
MMP-1, -3, and -13 and TIMP-1 in the conditioned
m e d i aw e r ea n a l y z e db yu s i n gc o m m e r c i a le n z y m e -
linked immunosorbent assay kits (ELISA; catalog no.
DMP100 for MMP-1, DMP300 for MMP-3, DM1300
for MMP-13, and DTM100 for TIMP-1, R&D Systems,
Minneapolis, MN, USA), which measured the pro-MMP
forms of MMP-1 and MMP-13 and the total forms for
MMP-3.
Western blotting
iNOS expression in adiponectin-stimulated OA chon-
drocytes was analyzed by immunoblotting by using anti-
iNOS (BD Biosciences, San Jose, CA, USA) and goat
anti-rabbit antibody (Zymed, San Francisco, CA, USA).
Adiponectin-stimulated activation of AMPK and JNK
was evaluated by using anti-phospho-AMPK and phos-
pho-JNK antibodies (Cell Signaling, Boston, MA, USA).
Reverse transcription polymerase chain reaction (RT-PCR)
RNA expression levels of iNOS and MMPs were semi-
quantitatively determined by using the RT-PCR with spe-
cific primer pairs; 5’-TCATCTTCGCCACCAAGCAGG-3’
and 5’-AGCATTCCACACCCGGAAGTC-3’ for iNOS
(GenBank Accession Number NM_000625), 5’-CCTT
CTACCCGGAAGTTGAG-3’ and 5’-TCCGTGTAGCA-
CATTCTGTC-3’ for MMP-1 (NM_002421), 5’-GAA
AGTCTGGGAAGAGGTGAC-3’ and 5’-AACCGAGT-
CAGGTCTGTGAG-3’ MMP-3 (NM_002422), and 5’-GA
ATTAAGGAGCATGGCGAC-3’ and 5’-TAAGGAGT
GGCCGAACTCAT-3’ for MMP-13 (NM_002427).
b-actin was used as the internal RT-PCR control by using
forward primer 5’-ACACTGTGCCCATCTACGAG-3’
and reverse primer 5’-TACAGGTCTTTGCGGATGTC-3’
(NM_001101).
Quantitative real-time RT-PCR was performed by
using the ABI-7500 real-time PCR machine (Applied
Biosystems, Foster City, CA, USA). The specific Taqman
primers and probes were purchased from Applied
Biosystems; iNOS (assay ID Hs00167248_m1), MMP-1
(Hs00233958_m1), MMP-3 (Hs00968308_m1), MMP-13
(Hs00233992_m1), and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH; Hs99999905). The number-
fold difference in the expression of target mRNA was
calculated by a comparative Ct method (2
-ΔΔCt), normal-
ized to GAPDH.
Measurement of collagenase-cleaved type II collagen
neoepitope
To assess cartilage matrix degradation, the harvested
OA cartilage tissue was cut into cubes of approximately
1 × 1 × 1 mm in size by using surgical blades. Cartilage
pieces weighing a total of approximately 200 mg were
placed into each well of a 24-well tissue plate with 1
ml/well of DMEM supplemented with 10% FBS. After 2
to 3 days, the cartilage explants were stimulated with
FBS-free DMEM including adiponectin (30 μg/ml) or
interleukin (IL)-1b (5 ng/ml) for 8 days. During the
treatment, the conditioned medium was harvested and
replaced every 4 days. The concentrations of collage-
nase-cleaved type II collagen product (C1-2C or COL2
¾ C short) were measured in the harvested media by
using a competitive immunoassay kit (catalog no. 60-
1002-001; IBEX Pharmaceuticals, Montreal, QC,
Canada) on days 4 and 8 after adiponectin treatment. In
brief, 50 μl/well of sample and 50 μl/well of diluted
anti-C1-2C antibody were preincubated in a polypropy-
lene mixing plate for 30 minutes at room temperature.
Eighty microliters per well of the mixture was
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1 hour and washing, 100 μl/well of goat anti-rabbit
horseradish peroxidase (HRP) conjugate was added and
incubated for 30 minutes. After repeated washing, the
plate was incubated for 30 minutes and then treated
with tetramethylbenzidine for another 30 minutes. The
reaction was stopped by using 100 μl/well of 0.2 M sul-
furic acid, and absorbance was measured at 450 nm.
Statistical analysis
Total NO, MMPs, TIMP-1, and C1-2C levels in the
conditioned media were measured in duplicate. Quanti-
tative real-time RT-PCR was performed in triplicate. To
compensate for interindividual variations, adipokine-
induced NO and MMPs/TIMP-1 levels are presented as
ratios versus nonstimulated levels. Continuous values
are presented as mean ± SEM. Statistical significance
was determined with the Mann-Whitney U test or Wil-
coxon matched-pairs signed-rank test using SPSS for
Windows version 11.0 (SPSS, Chicago, IL, USA), and
P values of < 0.05 were considered significant.
Results
Adiponectin receptors expression in OA cartilage
Immunohistochemical study demonstrated that all OA
cartilage samples expressed both AdipoR1 and AdipoR2;
AdipoR2 was expressed through all layers, whereas Adi-
poR1 was expressed mainly in the superficial layer of
OA cartilage (Figure 1a). Both AdipoR1 (49.0 ± 9.9%
versus 11.7 ± 4.6%; P < 0.05 by Wilcoxon matched-pairs
signed-rank test) and AdipoR2 (87.2 ± 2.7% versus 41.7 ±
6.9%; P < 0.05) were significant l ym o r ee x p r e s s e di nt h e
lesional cartilage area than in the nonlesional area.
When the expression levels of AdipoR1 and AdipoR2
were compared, the AdipoR2 was more strongly stained
than AdipoR1 in both nonlesional (staining intensity
score ranges from 1~2 versus 0~1) and lesional area
(staining intensity score ranges, 3 versus 1~3). Addition-
ally, the percentage of AdipoR2-positive chondrocytes
was significantly higher than that of AdipoR1-positive
chondrocytes in both nonlesional and lesional areas
(each P < 0.05). However, the counts of AdipoR1-
stained chondrocytes were increased at a higher rate
than those of AdipoR2-stained chondrocytes (4.2 versus
2.1 times; Figure 1b). The percentages of AdipoR1- or
AdipoR2-positive chondrocytes were not shown to be
correlated with either age or BMI.
Effects of adipokines on total NO production and iNOS
expression
Adiponectin-stimulated OA chondrocytes (the number of
samples, n = 6) significantly increased total NO produc-
tion in a dose-dependent manner (Figure 2a). Adiponectin
was also found to upregulate iNOS levels (Figure 2b).
Furthermore, adiponectin-induced NO production was
significantly inhibited by NOS inhibitors, L-NMMA and
L-NIL (n = 4) (Figure 2c).
Effects of adipokines on MMP-1, MMP-3, MMP-13 and
TIMP-1 secretion
Adiponectin increased the concentrations of MMP-1
(Figure 3a), MMP-3 (Figure 3b), and MMP-13 (Figure
3c) in the supernatants in a dose-dependent manner
(n = 6). However, TIMP-1 levels were not changed. Con-
sistent with ELISA results, quantitative RT-PCR showed
that MMP-1, -3, and -13 mRNA levels were upregulated
by 30 μg/ml of adiponectin (n = 4; Figure 4).
Effects of adipokines on the degradation of OA cartilage
matrix
The effect of the adiponectin on matrix degradation in OA
cartilage explants (n = 4) was evaluated ex vivo (Figure 5).
IL-1b served as a positive control. On days 4 and 8, the
levels of C1-2C were significantly increased in the super-
natants of cartilage explants cultures by 5 ng/ml of IL-1b.
In the meantime, C1-2C concentrations were significantly
elevated on day 8 with 30 μg/ml adiponectin.
Effect of protein kinase inhibitors on adiponectin-induced
production of MMPs and NO
Because adiponectin was a potential player in cartilage
degradation in vitro and ex vivo, we assessed signaling
pathways involved in adipokine-induced upregulation of
NO and MMPs. After plating OA chondrocytes (n =4 )
in wells coated with poly-HEMA, protein kinases were
added to the media 1 hour before adiponectin treatment
(30 μg/ml), and cells were incubated for 24 hours. Adi-
ponectin-induced total NO production was significantly
suppressed by inhibitors of NF-B, AMPK, and JNK
(Figure 6a). In addition, MMP-1 secretion was inhibited
by p38, AMPK, or JNK inhibitors (Figure 6b), MMP-3
by ERK, AMPK, and JNK inhibitors (Figure 6c), and
MMP-13 by all but NF-B inhibitor (Figure 6d). Espe-
cially AMPK and JNK inhibitors significantly suppressed
production of total NO and all three MMPs by 40% or
more, suggesting that AMPK-JNK axis is the major
pathway involved in adiponectin-induced biologic
actions. When examined with immunoblotting,
increased phospho-AMPK and phospho-JNK levels were
observed in adiponectin-stimulated OA chondrocytes
(Figure 7).
Effect of NOS inhibitors on adiponectin-induced
production of MMPs
Because adiponectin markedly enhanced NO produc-
tion in OA chondrocytes in the present study and
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expression of MMPs [17,18], the effects of NOS inhibi-
tors on adiponectin-induced MMPs production were
e v a l u a t e db yu s i n gan o n s e l e c t i v eN O Si n h i b i t o r ,L -
NMMA, and a selective iNOS inhibitor, L-NIL. Inter-
estingly, when the NOS inhibitors were added to
chondrocytes 24 hours before adiponectin stimulation,
both inhibitors significantly augmented adiponectin-
induced secretion of the three MMPs (n =4 )( F i g u r e
8). Especially the levels of MMP-13 were increased by
an average of 3.3-fold with L-NMMA and by an aver-
age of 2.8-fold with L-NIL.
Figure 1 Immunohistochemical staining for adiponectin receptor type 1 and type 2. Representative cartilage slides showed the expression
of AdipoR1 or AdipoR2 (aA, original magnification × 100). A nonlesional cartilage area revealed weakly AdipoR2-positive chondrocytes, but not
AdipoR1-positive chondrocytes. In a lesional cartilage area, AdipoR1 was stained mainly in the superficial layer (weak to strong staining intensity),
whereas AdipoR2 was stained in both superficial and deep layers of the lesional cartilage (strong staining intensity). The insert is a magnified
view (×400) of the area indicated by a red box. When compared between nonlesional and lesional areas, the expression levels of these two
receptors significantly increased in lesional areas (B, †P < 0.05 by Wilcoxon matched-pairs signed-rank test), and the increased rate of AdipoR1
(4.2 times) was as twice as high as that of AdipoR2 (2.1 times).
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Page 5 of 11Figure 2 Total NO production and iNOS expression in adiponectin-stimulated osteoarthritis (OA) chondrocytes. Adiponectin significantly
increased total NO production (n = 6, duplicate, P < 0.01) (A). Western blotting showed upregulation of iNOS expression in OA chondrocytes
stimulated with 30 μg/ml adiponectin (B). Both nonselective (L-NMMA, 2 mM) and selective NOS inhibitors (L-NIL, 50 μM) significantly prevented
total NO secretion (n = 4, duplicate, P < 0.05 for both) (c). The histogram with error bars represents the mean and the standard error of the mean.
*P < 0.01 by Mann-Whitney test; †P < 0.05 by Mann-Whitney test.
Figure 3 Effects of adiponectin on the expression of matrix metalloproteinase (MMP)-1, MMP-3, and MMP-13 in osteoarthritis (OA)
chondrocytes. In the conditioned media, adiponectin significantly increased the levels of MMP-1 (A) and MMP-3 (B), and MMP-13 (c) (n =6 ,
duplicate, P < 0.01 for all). The histogram with error bars represents the mean and the standard error of the mean. *P < 0.01 by Mann-Whitney
test; †P < 0.05 by Mann-Whitney test.
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The present study demonstrates that adiponectin
increased NO and three MMPs production in human
OA chondrocytes mainly via the AMPK-JNK pathway in
vitro and that adiponectin-induced NO and MMPs lead
to accelerated degradation of OA cartilage matrix ex vivo.
Our in vitro findings indicate that adiponectin is a
potential catabolic mediator in OA. This is in line with
the previous findings that adiponectin induces iNOS,
MMP-3, MMP-9, and MCP-1 in murine chondrocytes
[13]. More important, increased cartilage degradation
products after adiponectin treatment further supports
that in vitro catabolic activity induced by adiponectin is
relevant to cause cartilage degradation. Our result is in
parallel with the result of a recent study indicating that
the synovial fluid levels of adiponectin are correlated
with aggrecan degradation markers in patients with
knee OA [19]. However, Chen et al. [12] reported that
adiponectin did not alter the expression levels of
MMP-3 and MMP-13 mRNA. The contrasting results
regarding the effect of adiponectin might be due to
experimental conditions. Chen et al. used chondrocytes
from the OA knees with diverse severities and evaluated
the effects in monolayered cells at passages 3 to 7 [12],
whereas we isolated chondrocytes from the OA knees
with Kellgren-Lawrence grade 3 or 4 and grew them in
suspension at passage 0. Because OA chondrocyte beha-
vior and phenotypes can be affected by the surrounding
matrix state, culture methods, and passage numbers
[20], this might have contributed to the difference of
adiponectin-induced responses in each study.
Another possibility is a different composition of adipo-
nectin isoforms due to a different biologic source from
which adiponectin is produced. Native adiponectin has a
multimeric structure and circulates in blood as trimers,
hexamers, and high-molecular-weight (HMW) com-
plexes [14]. Biologic effects mediated by adiponectin
have been considered to be isoform dependent. HMW
adiponectin has pro-inflammatory effects [21,22],
whereas the low-molecular-weight (LMW) isoform has
antiinflammatory functions in human leukocytes and
monocytic cells [23,24]. We used HEK293 cell-derived
full-length adiponectin, the most abundant isoforms of
which are hexamers and HMW forms, followed by tri-
mers [25]. This composition is similar to that of human
OA synovial fluid in which hexamers and HMW forms
are the most abundant isoforms [12]. Conversely, full-
Figure 4 Reverse transcription polymerase chain reaction (RT-PCR) for iNOS and MMPs. Representative semiquantitative RT-PCR result for
iNOS and matrix metalloproteinases (MMPs) (A). Real-time RT-PCR demonstrated that adiponectin significantly increased the transcripts of iNOS
and all three MMPs in the osteoarthritis (OA) chondrocytes (n = 4, triplicate, P < 0.05) at 30 μg/ml (B). The histogram with error bars represents
the mean and the standard error of the mean. †P < 0.05 by Mann-Whitney test.
Figure 5 Effect of adiponectin on the degradation of
osteoarthritis (OA) cartilage matrix. IL-1b (5 ng/ml) significantly
increased the concentrations of collagenase-cleaved type II collagen
neoepitope (C1-2C) in conditioned media collected on days 4 and 8
(n = 4, duplicate, P < 0.05 for both). Adiponectin (30 μg/ml) also
showed increased the C1-2C levels in the media on day 8 (P <
0.05). The histogram with error bars represents the mean and the
standard error of the mean. †P < 0.05 by Mann-Whitney test.
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HMW forms [25]. Morevoer, adiponectin of the same
isoform could display a different potency to induce a
biologic response depending on whether it is E. coli
derived or mammalian cell derived [25,26]; adiponectin
produced in mammalian cells seems to be functionally
more potent than bacterially produced adiponectin
because the HMW form is a predominantly active form.
Because it is believed that E. coli-derived adiponectin
was used in the previous studies [12,13], pro-inflamma-
tory effects of adiponectin might not have been fully
developed in those studies.
Biologic effects of adiponectin are mediated mainly
through two receptors, AdipoR1 and AdipoR2, and
these two receptors are believed to activate different sig-
naling pathways; AdipoR1 activates the AMPK pathway,
whereas AdipoR2 is linked more closely with the peroxi-
some proliferator-activated receptor a (PPAR-a)p a t h -
way in the liver [27]. Chen et al. [12] showed that
human cartilage expressed only AdipoR1. However, our
study showed that both AdipoR1 and AdipoR2 are
expressed in human cartilage tissue, consistent with the
results of Lago et al. [13]. A heterogeneous distribution
of AdipoR1 and AdipoR2 on chondrocytes might be a
factor that explains the difference between our results
and those of the others. In our study, the expression of
AdipoR2 was higher in terms of the immunostaining
intensity as well as the percentage of stained cells, but
the increase rate of AdipoR1 was as twice as high as
that of AdipoR2, when nonlesional and lesional cartilage
areas were compared. This finding suggests that the
change of AdipoR1 expression might better reflect the
Figure 6 Effects of kinase inhibitors on the adiponectin-induced production of total NO (A), matrix metalloproteinase (MMP)-1 (B),
MMP-3 (C), and MMP-13 (D) in osteoarthritis (OA) chondrocytes. AMPK and JNK inhibitors (20 μM compound C and SP6000125,
respectively) significantly inhibited the production of total NO and all three MMPs (P < 0.05). NF-B (inhibited by 100 μg/ml SN50) was involved
in NO production, p38 MAP kinase (inhibited by 10 μM SB202190) in MMP-1 and -13, ERK (inhibited by 50 μM U0126) in MMP-3 and -13, and
Akt kinase (inhibited by 50 μM LY294002) in MMP-13 expressions. Experiments were performed on four samples in duplicates. The histogram
with error bars represents the mean and the standard error of the mean. The gray bars indicate significantly decreased total NO or MMP levels
by Mann-Whitney U test (†P < 0.05).
Figure 7 Adiponectin-induced AMPK and JNK phosphorylation.
When osteoarthritis (OA) chondrocytes were stimulated with 30 μg/
ml adiponectin, AMPK phosphorylation was increased after 15
minutes and peaked at 30 minutes. The levels of phospho-JNK were
increased 30 minutes after adiponectin stimulation.
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the AdipoR1-AMPK pathway could be associated with
cartilage catabolism.
It has been well established that adiponectin activates
AMPK [14]. Lago et al.[ 1 3 ]r e p o r t e dt h a tt h eA M P K /
Akt signaling pathway is involved in iNOS and MMP-3
induction by adiponectin in the murine chondrocyte
ATDC5 cell line. In addition, adiponectin activated the
AMPK/p38/NF-B axis in human synovial fibroblasts to
induce IL-6 production [15]. Conversely, in our study,
AMPK/JNK pathways are the major signaling pathway
involved in adiponectin-mediated induction of iNOS
and MMPs in human OA chondrocytes, whereas the
AMPK/Akt or AMPK/p38 pathway is partially involved
in MMP-13 or MMP-3 induction, respectively. The JNK
pathway is one of the signaling intermediates activated
by adiponectin [28,29], and adiponectin-induced JNK
activation has been shown to follow AMPK activation
[30,31]. Furthermore, JNK is involved in MMPs and
iNOS expression in human articular chondrocytes
[32-36]. Therefore, we expect that adiponectin induces
iNOS and MMP expression via JNK downstream to
AMPK in human chondrocytes and that the AMPK/JNK
axis is a major signaling system responsible for the adi-
ponectin-induced degradation of cartilage matrix.
Because NO can upregulate the expression or activity
of MMPs [17,18], we determined whether NO mediates
adiponectin-induced synthesis of MMPs. Unexpectedly,
the expression of MMPs was further increased by adipo-
nectin after pretreatment with a nonspecific NOS and a
specific iNOS inhibitor. This finding is consistent with
the previous observation by Hattori et al. [37] in which
adiponectin-induced NF-B activation was further
enhanced by a nonspecific NO inhibitor, L-NMMA, in
human umbilical vein endothelial cells. Interestingly,
LY294002, a PI3-K/Akt kinase inhibitor, significantly
suppressed NO production, whereas it caused a higher
MMP-3 production in adiponectin-treated ATDC5 cells
in the study of Lago et al. [13]. In this context, we are
tempted to speculate that NO serves as a negative-
feedback regulator of adiponectin action in cartilage,
and that this negative feedback may lead to the delayed
effects of adiponectin on the OA cartilage catabolism
when compared with those of IL-1b in our study. The
role of NO as a catabolic mediator has been controver-
sial. The protective effect of NO on cartilage degrada-
tion has been shown by several studies [38-40], in which
the treatment with NOS inhibitors accelerated the
proteoglycan breakdown by increasing MMP levels in
culture media [38]. Thus, the exact role of NO in carti-
lage homeostasis seems to be complex. Further studies
on the effect of NO on AMPK or JNK activation in
chondrocytes will elucidate the mechanisms by which
NO influences adiponectin-induced MMP production.
We used the highest dosage (30 μg/ml) of adiponectin
with maximal biologic activity to investigate the full
catabolic potential of adiponectin. Because adiponectin
concentrations in OA synovial fluid are typically lower
(1 to 5 μg/ml) than the doses used in our study [11], a
possibility exists that the catabolic effect of adiponectin
is overemphasized in our study. However, the human
OA joint tissues including cartilage were reported to
release adiponectin in ex vivo culture study [11], and
ATDC5 cells have been shown to express adiponectin
themselves in an autocrine manner [41]. Therefore, the
actual concentrations of adiponectin might be higher in
the microenvironment surrounding chondrocytes than
those measured in OA synovial fluid.
Conclusions
The present study suggests that adiponectin induces
MMPs and iNOS expression via the AMPK/JNK
Figure 8 Effects of iNOS inhibitors on the adiponectin-induced production of matrix metalloproteinases MMPs in osteoarthritis (OA)
chondrocytes. A nonselective NOS inhibitor (L-NMMA, 2 mM) and a specific iNOS inhibitor (L-NIL, 50 μM) significantly enhanced MMP-1 (A),
MMP-3 (B), and MMP-13 (C) expressions induced by adiponectin (30 μg/ml). Experiments were performed on four samples in duplicates. The
histogram with error bars represents the mean and the standard error of the mean. †P < 0.05 by Mann-Whitney test.
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Page 9 of 11pathway, and it may play a potential role in OA cartilage
catabolism.
Abbreviations
AdipoR: adiponectin receptor; AMPK: AMP-activated protein kinase; C1-2C:
collagenase-cleaved type II collagen neoepitope; DMEM: Dulbecco’s
Modified Eagle Medium; FBS: fetal bovine serum; ELISA: enzyme-linked
immunosorbent assay kits; ERK: extracellular-regulated kinase; HEMA:
hydroxyethyl methacrylate; iNOS: inducible nitric oxide synthase; JNK: c-Jun
N-terminal kinase; L-NIL: L-N
6-(1-iminoethyl)-lysine; L-NMMA: L-N
G-
monomethyl arginine citrate; MMP: matrix metalloproteinase; NF-κB: nuclear
factor kappa B; NO: nitric oxide; NOS: nitric oxide synthase; OA: osteoarthritis;
RT-PCR: reverse transcription polymerase chain reaction; TIMP: tissue inhibitor
of metalloproteinase.
Acknowledgements
This work was supported by the Seoul National University Bundang Hospital
Research Fund (grant number 03-04-004) and by the Korea Research
Foundation Grant funded by the Korean Government (MOEHRD) (KRF-2006-
331-E00151).
Author details
1Department of Internal Medicine, Seoul National University Bundang
Hospital, 166 Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea, 463-
707.
2Department of Internal Medicine, Seoul National University College of
Medicine, 28 Yeongeon-dong, Jongro-gu, Seoul, Korea, 110-799.
3Department of Orthopedic Surgery, Seoul National University Bundang
Hospital, 166 Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea, 463-
707.
4Department of Pathology, Seoul National University Bundang Hospital,
166 Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea, 463-707.
5Department of Internal Medicine, Seoul National University Hospital, 28
Yeongeon-dong, Jongro-gu, Seoul, Korea, 110-744.
Authors’ contributions
EHK was involved in the acquisition and interpretation of data and prepared
the initial draft of the manuscript. YJL conceived and designed the study,
participated in the analysis and interpretation of data, and revised the
manuscript. TKK and CJB participated in the design of the study, collected
the OA cartilage samples, and were involved in the critical revision of the
manuscript. JHC was involved in the acquisition and interpretation of
immunohistochemical data and in the revision of the manuscript. KS, EYL,
EBL, and YWS participated in the design of the study and were involved in
the analysis and interpretation of the data and in the critical revision of the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 24 April 2010 Revised: 31 October 2010
Accepted: 31 December 2010 Published: 31 December 2010
References
1. Englund M, Lohmander LS: Risk factors for symptomatic knee
osteoarthritis fifteen to twenty-two years after meniscectomy. Arthritis
Rheum 2004, 50:2811-2819.
2. Cooper C, Snow S, McAlindon TE, Kellingray S, Stuart B, Coggon D,
Dieppe PA: Risk factors for the incidence and progression of
radiographic knee osteoarthritis. Arthritis Rheum 2000, 43:995-1000.
3. Hart DJ, Spector TD: The relationship of obesity, fat distribution and
osteoarthritis in women in the general population: the Chingford Study.
J Rheumatol 1993, 20:331-315.
4. Felson DT, Zhang Y, Anthony JM, Naimark A, Anderson JJ: Weight loss
reduces the risk for symptomatic knee osteoarthritis in women: The
Framingham Study. Ann Intern Med 1992, 116:535-539.
5. Sharma L, Chang A: Overweight: advancing our understanding of its
impact on the knee and the hip. Ann Rheum Dis 2007, 66:141-142.
6. Pottie P, Presle N, Terlain B, Netter P, Mainard D, Berenbaum F: Obesity and
osteoarthritis: more complex than predicted. Ann Rheum Dis 2006,
65:1403-1405.
7. Meier U, Gressner AM: Endocrine regulation of energy metabolism:
review of pathobiochemical and clinical chemical aspects of leptin,
ghrelin, adiponectin, and resistin. Clin Chem 2004, 50:1511-1525.
8. Laurberg TB, Frystyk J, Ellingsen T, Hansen IT, Jørgensen A, Tarp U,
Hetland ML, Hørslev-Petersen K, Hornung N, Poulsen JH, Flyvbjerg A,
Stengaard-Pedersen K: Plasma adiponectin in patients with active, early,
and chronic rheumatoid arthritis who are steroid- and disease-
modifying antirheumatic drug-naive compared with patients with
osteoarthritis and controls. J Rheumatol 2009, 36:1885-1891.
9. Filková M, Lisková M, Hulejová H, Haluzík M, Gatterová J, Pavelková A,
Pavelka K, Gay S, Müller-Ladner U, Senolt L: Increased serum adiponectin
levels in female patients with erosive compared with non-erosive
osteoarthritis. Ann Rheum Dis 2009, 68:295-296.
10. Schäffler A, Ehling A, Neumann E, Herfarth H, Tarner I, Schölmerich J,
Müller-Ladner U, Gay S: Adipocytokines in synovial fluid. JAMA 2003,
290:1709-1710.
11. Presle N, Pottie P, Dumond H, Guillaume C, Lapicque F, Pallu S, Mainard D,
Netter P, Terlain B: Differential distribution of adipokines between serum
and synovial fluid in patients with osteoarthritis: contribution of joint
tissues to their articular production. Osteoarthritis Cartilage 2006,
14:690-695.
12. Chen TH, Chen L, Hsieh MS, Chang CP, Chou DT, Tsai SH: Evidence for a
protective role for adiponectin in osteoarthritis. Biochim Biophys Acta
2006, 1762:711-718.
13. Lago R, Gomez R, Otero M, Lago F, Gallego R, Dieguez C, Gomez-Reino JJ,
Gualillo O: A new player in cartilage homeostasis: adiponectin induces
nitric oxide synthase type II and pro-inflammatory cytokines in
chondrocytes. Osteoarthritis Cartilage 2008, 16:1101-1109.
14. Kadowaki T, Yamauchi T: Adiponectin and adiponectin receptors. Endocr
Rev 2005, 26:439-451.
15. Tang CH, Chiu YC, Tan TW, Yang RS, Fu WM: Adiponectin enhances IL-6
production in human synovial fibroblast via an AdipoR1 receptor, AMPK,
p38, and NF-kappa B pathway. J Immunol 2007, 179:5483-5492.
16. Reginato AM, Iozzo RV, Jimenez SA: Formation of nodular structures
resembling mature articular cartilage in long-term primary cultures of
human fetal epiphyseal chondrocytes on a hydrogel substrate. Arthritis
Rheum 1994, 37:1338-1349.
17. Tamura T, Nakanishi T, Kimura Y, Hattori T, Sasaki K, Norimatsu H,
Takahashi K, Takigawa M: Nitric oxide mediates interleukin-1-induced
matrix degradation and basic fibroblast growth factor release in
cultured rabbit articular chondrocytes: a possible mechanism of
pathological neovascularization in arthritis. Endocrinology 1996,
137:3729-3737.
18. Murrell GA, Jang D, Williams RJ: Nitric oxide activates metalloprotease
enzymes in articular cartilage. Biochem Biophys Res Commun 1995,
206:15-21.
19. Hao D, Li M, Wu Z, Duan Y, Li D, Qiu G: Synovial fluid level of adiponectin
correlated with levels of aggrecan degradation markers in osteoarthritis.
Rheumatol Int 2010.
20. Aigner T, Söder S, Gebhard PM, McAlinden A, Haag J: Mechanisms of
disease: role of chondrocytes in the pathogenesis of osteoarthritis:
structure, chaos and senescence. Nat Clin Pract Rheumatol 2007,
3:391-399.
21. Haugen F, Drevon CA: Activation of nuclear factor-kappaB by high
molecular weight and globular adiponectin. Endocrinology 2007,
148:5478-5486.
22. Song H, Chan J, Rovin BH: Induction of chemokine expression by
adiponectin in vitro is isoform dependent. Transl Res 2009, 154:18-26.
23. Schober F, Neumeier M, Weigert J, Wurm S, Wanninger J, Schäffler A,
Dada A, Liebisch G, Schmitz G, Aslanidis C, Buechler C: Low molecular
weight adiponectin negatively correlates with the waist circumference
and monocytic IL-6 release. Biochem Biophys Res Commun 2007,
361:968-973.
24. Neumeier M, Weigert J, Schäffler A, Wehrwein G, Müller-Ladner U,
Schölmerich J, Wrede C, Buechler C: Different effects of adiponectin
isoforms in human monocytic cells. J Leukoc Biol 2006, 79:803-808.
25. Tsao TS, Murrey HE, Hug C, Lee DH, Lodish HF: Oligomerization state-
dependent activation of NF-kappa B signaling pathway by adipocyte
complement-related protein of 30 kDa (Acrp30). J Biol Chem 2002,
277:29359-29362.
Kang et al. Arthritis Research & Therapy 2010, 12:R231
http://arthritis-research.com/content/12/6/R231
Page 10 of 1126. Wang Y, Xu A, Knight C, Xu LY, Cooper GJ: Hydroxylation and
glycosylation of the four conserved lysine residues in the collagenous
domain of adiponectin: potential role in the modulation of its insulin-
sensitizing activity. J Biol Chem 2002, 277:19521-19529.
27. Yamauchi T, Kadowaki T: Physiological and pathophysiological roles of
adiponectin and adiponectin receptors in the integrated regulation of
metabolic and cardiovascular diseases. Int J Obes (Lond) 2008, 32(suppl
7):S13-S18.
28. Luo XH, Guo LJ, Yuan LQ, Xie H, Zhou HD, Wu XP, Liao EY: Adiponectin
stimulates human osteoblasts proliferation and differentiation via the
MAPK signaling pathway. Exp Cell Res 2005, 309:99-109.
29. Miyazaki T, Bub JD, Uzuki M, Iwamoto Y: Adiponectin activates c-Jun NH2-
terminal kinase and inhibits signal transducer and activator of
transcription 3. Biochem Biophys Res Commun 2005, 333:79-87.
30. Lee YM, Uhm KO, Lee ES, Kwon J, Park SH, Kim HS: AM251 suppresses the
viability of HepG2 cells through the AMPK (AMP-activated protein
kinase)-JNK (c-Jun N-terminal kinase)-ATF3 (activating transcription
factor 3) pathway. Biochem Biophys Res Commun 2008, 370:641-645.
31. Saxena NK, Fu PP, Nagalingam A, Wang J, Handy J, Cohen C, Tighiouart M,
Sharma D, Anania FA: Adiponectin modulates C-Jun N-terminal kinase
and mammalian target of rapamycin and inhibits hepatocellular
carcinoma. Gastroenterology 2010, 139:1762-1773.
32. Nishitani K, Ito H, Hiramitsu T, Tsutsumi R, Tanida S, Kitaori T, Yoshitomi H,
Kobayashi M, Nakamura T: PGE2 inhibits MMP expression by suppressing
MKK4-JNK-MAP kinase-c-JUN pathway via EP4 in human articular
chondrocytes. J Cell Biochem 2010, 109:425-433.
33. Legendre F, Bogdanowicz P, Martin G, Domagala F, Leclercq S, Pujol JP,
Ficheux H: Rhein, a diacerhein-derived metabolite, modulates the
expression of matrix degrading enzymes and the cell proliferation of
articular chondrocytes by inhibiting ERK and JNK-AP-1 dependent
pathways. Clin Exp Rheumatol 2007, 25:546-555.
34. Ho LJ, Lin LC, Hung LF, Wang SJ, Lee CH, Chang DM, Lai JH, Tai TY:
Retinoic acid blocks pro-inflammatory cytokine-induced matrix
metalloproteinase production by down-regulating JNK-AP-1 signaling in
human chondrocytes. Biochem Pharmacol 2005, 70:200-208.
35. Chan ED, Riches DW: Potential role of the JNK/SAPK signal transduction
pathway in the induction of iNOS by TNF-alpha. Biochem Biophys Res
Commun 1998, 253:790-796.
36. Huang CY, Hung LF, Liang CC, Ho LJ: COX-2 and iNOS are critical in
advanced glycation end product-activated chondrocytes in vitro. Eur J
Clin Invest 2009, 39:417-428.
37. Hattori Y, Nakano Y, Hattori S, Tomizawa A, Inukai K, Kasai K: High
molecular weight adiponectin activates AMPK and suppresses cytokine-
induced NF-kappaB activation in vascular endothelial cells. FEBS Lett
2008, 582:1719-1724.
38. Stefanovic-Racic M, Möllers MO, Miller LA, Evans CH: Nitric oxide and
proteoglycan turnover in rabbit articular cartilage. J Orthop Res 1997,
15:442-449.
39. Stefanovic-Racic M, Morales TI, Taskiran D, McIntyre LA, Evans CH: The role
of nitric oxide in proteoglycan turnover by bovine articular cartilage
organ cultures. J Immunol 1996, 156:1213-1220.
40. Häuselmann HJ, Stefanovic-Racic M, Michel BA, Evans CH: Differences in
nitric oxide production by superficial and deep human articular
chondrocytes: implications for proteoglycan turnover in inflammatory
joint diseases. J Immunol 1998, 160:1444-1448.
41. Challa TD, Rais Y, Ornan EM: Effect of adiponectin on ATDC5 proliferation,
differentiation and signaling pathways. Mol Cell Endocrinol 2010,
323:282-291.
doi:10.1186/ar3218
Cite this article as: Kang et al.: Adiponectin is a potential catabolic
mediator in osteoarthritis cartilage. Arthritis Research & Therapy 2010 12:
R231.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kang et al. Arthritis Research & Therapy 2010, 12:R231
http://arthritis-research.com/content/12/6/R231
Page 11 of 11